CL2015003422A1 - Compositions, methods and systems for respiratory delivery of three or more active agents - Google Patents

Compositions, methods and systems for respiratory delivery of three or more active agents

Info

Publication number
CL2015003422A1
CL2015003422A1 CL2015003422A CL2015003422A CL2015003422A1 CL 2015003422 A1 CL2015003422 A1 CL 2015003422A1 CL 2015003422 A CL2015003422 A CL 2015003422A CL 2015003422 A CL2015003422 A CL 2015003422A CL 2015003422 A1 CL2015003422 A1 CL 2015003422A1
Authority
CL
Chile
Prior art keywords
compositions
systems
methods
active agents
respiratory delivery
Prior art date
Application number
CL2015003422A
Other languages
Spanish (es)
Inventor
Colin Reisner
Patrick Fitzgerald Darken
David Lechuga-Ballesteros
Vidya B Joshi
Sarvajna Kumar Dwivedi
Original Assignee
Pearl Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pearl Therapeutics Inc filed Critical Pearl Therapeutics Inc
Publication of CL2015003422A1 publication Critical patent/CL2015003422A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

COMPOSICION EN SUSPENSION PARA SUMINISTRO POR VIA RESPIRATORIA DE UN ANTAGONISTA MUSCARINICO DE ACCION PROLONGADA (LAMA), UN AGONISTA BETA-ADRENERGICO DE ACCION PROLONGADA (LABA) Y UN CORTICOSTEROIDE (ICS); SU USO PARA TRATAR UNA ENFERMEDAD O TRASTORNO PULMONAR TAL COMO ASMA, EPOC, INFLAMACION, ALERGIAS, HIPERTENSION PULMONAR, ENTRE OTRAS.SUSPENSION COMPOSITION FOR SUPPLY BY RESPIRATORY ROUTE OF A PROLONGED ACTION MUSCARINIC ANTAGONIST (LAMA), A BETA-ADRENERGIC PROLONGED ACTION (LABA) AND A CORTICOSTEROID (ICS); ITS USE TO TREAT A PULMONARY DISEASE OR DISORDER AS AS ASTHMA, COPD, INFLAMMATION, ALLERGIES, PULMONARY HYPERTENSION, AMONG OTHERS.

CL2015003422A 2013-05-22 2015-11-20 Compositions, methods and systems for respiratory delivery of three or more active agents CL2015003422A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361826424P 2013-05-22 2013-05-22

Publications (1)

Publication Number Publication Date
CL2015003422A1 true CL2015003422A1 (en) 2016-09-02

Family

ID=50942948

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003422A CL2015003422A1 (en) 2013-05-22 2015-11-20 Compositions, methods and systems for respiratory delivery of three or more active agents

Country Status (20)

Country Link
US (1) US20150150787A1 (en)
EP (1) EP2999460A1 (en)
JP (1) JP2016519160A (en)
KR (1) KR20160013134A (en)
CN (1) CN105392471A (en)
AU (1) AU2014268482A1 (en)
BR (1) BR112015028964A2 (en)
CA (1) CA2912927A1 (en)
CL (1) CL2015003422A1 (en)
CR (1) CR20150645A (en)
DO (1) DOP2015000284A (en)
HK (2) HK1221653A1 (en)
MX (1) MX2015016058A (en)
NI (1) NI201500163A (en)
PE (1) PE20160155A1 (en)
PH (1) PH12015502593A1 (en)
RU (1) RU2015154720A (en)
SG (1) SG11201509543YA (en)
WO (1) WO2014190204A1 (en)
ZA (1) ZA201509016B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2435023B1 (en) 2009-05-29 2016-07-06 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta 2 adrenergic receptor agonists and associated methods and systems
EP3485906A1 (en) * 2012-03-09 2019-05-22 Pfizer Inc Neisseria meningitidis compositions and methods thereof
JP6397025B2 (en) * 2013-11-22 2018-09-26 テバ ブランデッド ファーマシューティカル プロダクツ アール アンド ディー インコーポレイテッド Inhalable drug
MA40617B1 (en) 2014-09-09 2020-05-29 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
WO2017108917A1 (en) * 2015-12-22 2017-06-29 Astrazeneca Ab Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
WO2019142214A1 (en) 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
WO2020123057A2 (en) * 2018-10-31 2020-06-18 Repurposed Therapeutics, Inc. Dba Defender Treatment of exposure to chlorine gas with scopolamine
CN112137957B (en) * 2019-06-26 2022-07-29 长风药业股份有限公司 Medicinal inhalation aerosol and preparation method thereof
CN111349036B (en) * 2020-03-13 2022-03-08 安徽恒星制药有限公司 Glycopyrronium bromide substitute, and preparation method and medical application thereof
CN111467498A (en) * 2020-05-14 2020-07-31 王兆霖 Pharmaceutical composition preparation
CN111617138A (en) * 2020-07-07 2020-09-04 上海凯宝药业股份有限公司 Application of phlegm-heat clearing medicine in preparation of medicine for treating acute exacerbation of chronic obstructive pulmonary disease
IL309888A (en) * 2021-07-09 2024-03-01 Astrazeneca Pharmaceuticals Lp Compositions, methods and systems for aerosol drug delivery
WO2023119093A1 (en) * 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (en) 1972-05-19 1975-08-18 Bofors Ab
ATE8790T1 (en) 1981-02-02 1984-08-15 Schering Corporation AROMATIC HETEROCYCLIC STEROID ESTER, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
SE9302777D0 (en) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
SE9404080L (en) 1993-12-28 1995-06-29 Ciba Geigy Ag Process for preparing an optically pure enantiomer of formoterol
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (en) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmaceutical nanosuspensions for drug application as systems with increased saturation solubility and dissolution rate
US6136346A (en) 1995-04-14 2000-10-24 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5886200A (en) 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
PT102343B (en) 1999-08-02 2003-11-28 Hovione Farmaciencia Sa METHOD FOR THE PREPARATION OF FUROATE MOMETHASONE
PT1666028E (en) 1999-10-29 2010-06-15 Novartis Ag Dry powder compositions having improved dispersivity
US7862834B2 (en) 2003-05-28 2011-01-04 Novartis Pharma Ag Pharmaceutical formulation comprising a water-insoluble active agent
EP1904219A4 (en) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc Method of particle formation
EP2435023B1 (en) * 2009-05-29 2016-07-06 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta 2 adrenergic receptor agonists and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US20140308214A1 (en) * 2011-02-17 2014-10-16 Cipla Limited Pharmaceutical Composition
CN103687483A (en) * 2011-05-17 2014-03-26 珍珠治疗公司 Compositions, methods & systems for respiratory delivery of two or more active agents

Also Published As

Publication number Publication date
US20150150787A1 (en) 2015-06-04
CR20150645A (en) 2016-02-10
CA2912927A1 (en) 2014-11-27
BR112015028964A2 (en) 2017-07-25
WO2014190204A1 (en) 2014-11-27
PH12015502593A1 (en) 2016-02-29
ZA201509016B (en) 2018-07-25
EP2999460A1 (en) 2016-03-30
KR20160013134A (en) 2016-02-03
HK1221654A1 (en) 2017-06-09
SG11201509543YA (en) 2015-12-30
JP2016519160A (en) 2016-06-30
DOP2015000284A (en) 2016-04-29
CN105392471A (en) 2016-03-09
PE20160155A1 (en) 2016-04-01
MX2015016058A (en) 2016-12-20
HK1221653A1 (en) 2017-06-09
NI201500163A (en) 2016-01-06
AU2014268482A1 (en) 2016-01-07
RU2015154720A (en) 2017-06-27

Similar Documents

Publication Publication Date Title
CL2015003422A1 (en) Compositions, methods and systems for respiratory delivery of three or more active agents
CL2017000969A1 (en) Compositions of factor viii and methods for making and using them (divisional application no. 2166-2014)
CO2017004649A2 (en) Neuroactive steroids for CNS disorders
ECSP21072161A (en) LINACLOTIDE DELAYED RELEASE COMPOSITIONS
UY34984A (en) METHODS TO TREAT OR PREVENT ASTHMA BY MANAGING AN IL-4R ANTAGONIST.
CL2016000187A1 (en) Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2 (1h) -one derivatives that have muscarinic receptor antagonist activity as well as b2 adrenergic receptor agonist activity.
GT201400016A (en) INDAZOLES
CO6771417A2 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis
BR112015004984A2 (en) stable aqueous formulations of adalimumab
BR112015022191A2 (en) heteroaryl compounds, their use and composition comprising them
BR112014030060A2 (en) tetrahydropyrazolopyrimidine compounds
CL2008000911A1 (en) COMPOUNDS DERIVED FROM PYRIMIDINE, PROSTAGLANDIN D2 INHIBITORS; PHARMACEUTICAL COMPOSITION; AND USE TO TREAT AN ALLERGIC OR INFLAMMATORY DISORDER SUCH AS ALLERGIC RHINITIS, ASTHMA AND COPD.
CU24397B1 (en) DERIVATIVES OF PIPERIDINIL-INDOL AS INHIBITORS OF THE COMPLEMENT FACTOR B
CL2014001486A1 (en) Urea-derived compounds, kinase inhibitors; pharmaceutical composition that includes them; use in the treatment of diseases such as chronic eosinophilic pneumonia, asthma, copd, respiratory distress syndrome in adults (ards), among others.
NI201400107A (en) HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS
CL2015001724A1 (en) Compounds derived from peptides, oxytocin agonists; pharmaceutical composition; and its use for the treatment of autism, stress, anxiety, depression, schizophrenia, among others.
CL2016001543A1 (en) Isocromen derivatives as inhibitors of phosphoinositido-3 kinases.
CL2014002915A1 (en) Compounds derived from imidazothiadiazole and imidazopyrazine, as inhibitors of the activated protease 4 receptor (par4); pharmaceutical composition that includes them; and its use to inhibit or prevent platelet aggregation and therefore useful in the treatment of a thromboembolic disorder or for the primary or secondary prophylaxis of a thromboembolic disorder.
DOP2014000008A (en) 4-IMIDAZOPIRIDAZINA-1-IL-BENZAMIDAS AND 4-IMIDAZOTRIAZINA-1-IL-BENZAMIDAS AS BTK INHIBITORS
CO6640327A2 (en) Pyrazole compounds as sigma receptor inhibitors
CL2013003731A1 (en) Compounds derived from carboxamide; pharmaceutical composition that includes them, and their use as inhibitors of phosphodiesterase type 10a (pde10a) for the treatment of CNS disorders, schizophrenia, cognitive dysfunction related to schizophrenia, bipolar disorders, depression, cognitive dysfunction, cognitive disorders, behavioral disorders associated with Alzheimer's disease, obesity, huntington's disease and anxiety.
UY35391A (en) 2-AZA-BICYCLE ACID [2.2.1] HEPTANO-3-CARBOXILICO (BENCIL-CYANOMETIL) -CATPSIN C INHIBITING REPLACED MEASURES
PE20150631A1 (en) CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR
FI20145771L (en) Parasiticidal oral veterinary drug compositions comprising systemically acting active agents, methods and uses thereof
UY32926A (en) COMPOUNDS AS ANTAGONISTS OF LISOPHOSPHATIDIC ACID RECEPTORS